Providing personalized prognostic information for adult leukemia survivors

Stephanie J. Lee; Barry Storer; Hailin Wang; Hillard M. Lazarus; Edmund K. Waller; Luis M. Isola; Thomas R. Klumpp; John Bosco C Umejiego; Bipin N. Savani; Alison W. Loren; Mitchell S. Cairo; Bruce M. Camitta; Corey S. Cutler; Biju George; H. Jean Khoury; David I. Marks; David A. Rizzieri; Edward A. Copelan; Vikas Gupta; Jane L. Liesveld; Mark R. Litzow; Alan M. Miller; Harry C. Schouten; Robert Peter Gale; Jean Yves Cahn; Daniel J. Weisdorf

doi:10.1016/j.bbmt.2013.08.013

Providing personalized prognostic information for adult leukemia survivors

Stephanie J. Lee, Barry Storer, Hailin Wang, Hillard M. Lazarus, Edmund K. Waller, Luis M. Isola, Thomas R. Klumpp, John Bosco C Umejiego, Bipin N. Savani, Alison W. Loren, Mitchell S. Cairo, Bruce M. Camitta, Corey S. Cutler, Biju George, H. Jean Khoury, David I. Marks, David A. Rizzieri, Edward A. Copelan, Vikas Gupta, Jane L. LiesveldMark R. Litzow, Alan M. Miller, Harry C. Schouten, Robert Peter Gale, Jean Yves Cahn, Daniel J. Weisdorf

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Prediction of subsequent leukemia-free survival (LFS) and chronic graft-versus-host disease (GVHD) in adults with acute leukemia who survived at least 1 year after allogeneic hematopoietic cell transplantation is difficult. We analyzed 3339 patients with acute myeloid leukemia and 1434 patients with acute lymphoblastic leukemia who received myeloablative conditioning and related or unrelated stem cells from 1990 to 2005. Most clinical factors predictive of LFS in 1-year survivors were no longer significant after 2 or more years. For acute myeloid leukemia, only disease status (beyond first complete remission) remained a significant adverse risk factor for LFS 2 or more years after transplantation. For lymphoblastic leukemia, only extensive chronic GVHD remained a significant adverse predictor of LFS in the second and subsequent years. For patients surviving for 1 year without disease relapse or extensive chronic GVHD, the risk of developing extensive chronic GVHD in the next year was 4% if no risk factors were present and higher if noncyclosporine-based GVHD prophylaxis, an HLA-mismatched donor, or peripheral blood stem cells were used. Estimates for subsequent LFS and extensive chronic GVHD can be derived for individual patients or populations using an online calculator (http://www.cibmtr.org/LeukemiaCalculators). This prognostic information is more relevant for survivors than estimates provided before transplantation.

Original language	English (US)
Pages (from-to)	1600-1607
Number of pages	8
Journal	Biology of Blood and Marrow Transplantation
Volume	19
Issue number	11
DOIs	https://doi.org/10.1016/j.bbmt.2013.08.013
State	Published - Nov 2013

Bibliographical note

Funding Information:
Financial Disclosure: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases ; a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration; 2 grants ( N00014-06-1-0704 and N00014-08-1-0058 ) from the Office of Naval Research ; and grants from Allos, Inc. ; Amgen, Inc. ; Angioblast ; anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; HistoGenetics, Inc.; Kiadis Pharma; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; RemedyMD; Sanofi; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government.

Keywords

Chronic graft-versus-host disease
Landmark analysis
Leukemia-free survival
Prognosis
Survivorship

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.bbmt.2013.08.013

OpenUrl availability

Full text

Cite this

Lee, S. J., Storer, B., Wang, H., Lazarus, H. M., Waller, E. K., Isola, L. M., Klumpp, T. R., Umejiego, J. B. C., Savani, B. N., Loren, A. W., Cairo, M. S., Camitta, B. M., Cutler, C. S., George, B., Jean Khoury, H., Marks, D. I., Rizzieri, D. A., Copelan, E. A., Gupta, V., ... Weisdorf, D. J. (2013). Providing personalized prognostic information for adult leukemia survivors. Biology of Blood and Marrow Transplantation, 19(11), 1600-1607. https://doi.org/10.1016/j.bbmt.2013.08.013

Lee, SJ, Storer, B, Wang, H, Lazarus, HM, Waller, EK, Isola, LM, Klumpp, TR, Umejiego, JBC, Savani, BN, Loren, AW, Cairo, MS, Camitta, BM, Cutler, CS, George, B, Jean Khoury, H, Marks, DI, Rizzieri, DA, Copelan, EA, Gupta, V, Liesveld, JL, Litzow, MR, Miller, AM, Schouten, HC, Gale, RP, Cahn, JY & Weisdorf, DJ 2013, 'Providing personalized prognostic information for adult leukemia survivors', Biology of Blood and Marrow Transplantation, vol. 19, no. 11, pp. 1600-1607. https://doi.org/10.1016/j.bbmt.2013.08.013

@article{b65c98aa38d542e6a35f92e7519649b9,

title = "Providing personalized prognostic information for adult leukemia survivors",

abstract = "Prediction of subsequent leukemia-free survival (LFS) and chronic graft-versus-host disease (GVHD) in adults with acute leukemia who survived at least 1 year after allogeneic hematopoietic cell transplantation is difficult. We analyzed 3339 patients with acute myeloid leukemia and 1434 patients with acute lymphoblastic leukemia who received myeloablative conditioning and related or unrelated stem cells from 1990 to 2005. Most clinical factors predictive of LFS in 1-year survivors were no longer significant after 2 or more years. For acute myeloid leukemia, only disease status (beyond first complete remission) remained a significant adverse risk factor for LFS 2 or more years after transplantation. For lymphoblastic leukemia, only extensive chronic GVHD remained a significant adverse predictor of LFS in the second and subsequent years. For patients surviving for 1 year without disease relapse or extensive chronic GVHD, the risk of developing extensive chronic GVHD in the next year was 4% if no risk factors were present and higher if noncyclosporine-based GVHD prophylaxis, an HLA-mismatched donor, or peripheral blood stem cells were used. Estimates for subsequent LFS and extensive chronic GVHD can be derived for individual patients or populations using an online calculator (http://www.cibmtr.org/LeukemiaCalculators). This prognostic information is more relevant for survivors than estimates provided before transplantation.",

keywords = "Chronic graft-versus-host disease, Landmark analysis, Leukemia-free survival, Prognosis, Survivorship",

author = "Lee, {Stephanie J.} and Barry Storer and Hailin Wang and Lazarus, {Hillard M.} and Waller, {Edmund K.} and Isola, {Luis M.} and Klumpp, {Thomas R.} and Umejiego, {John Bosco C} and Savani, {Bipin N.} and Loren, {Alison W.} and Cairo, {Mitchell S.} and Camitta, {Bruce M.} and Cutler, {Corey S.} and Biju George and {Jean Khoury}, H. and Marks, {David I.} and Rizzieri, {David A.} and Copelan, {Edward A.} and Vikas Gupta and Liesveld, {Jane L.} and Litzow, {Mark R.} and Miller, {Alan M.} and Schouten, {Harry C.} and Gale, {Robert Peter} and Cahn, {Jean Yves} and Weisdorf, {Daniel J.}",

note = "Funding Information: Financial Disclosure: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases ; a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration; 2 grants ( N00014-06-1-0704 and N00014-08-1-0058 ) from the Office of Naval Research ; and grants from Allos, Inc. ; Amgen, Inc. ; Angioblast ; anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; HistoGenetics, Inc.; Kiadis Pharma; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; RemedyMD; Sanofi; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government.",

year = "2013",

month = nov,

doi = "10.1016/j.bbmt.2013.08.013",

language = "English (US)",

volume = "19",

pages = "1600--1607",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Providing personalized prognostic information for adult leukemia survivors

AU - Lee, Stephanie J.

AU - Storer, Barry

AU - Wang, Hailin

AU - Lazarus, Hillard M.

AU - Waller, Edmund K.

AU - Isola, Luis M.

AU - Klumpp, Thomas R.

AU - Umejiego, John Bosco C

AU - Savani, Bipin N.

AU - Loren, Alison W.

AU - Cairo, Mitchell S.

AU - Camitta, Bruce M.

AU - Cutler, Corey S.

AU - George, Biju

AU - Jean Khoury, H.

AU - Marks, David I.

AU - Rizzieri, David A.

AU - Copelan, Edward A.

AU - Gupta, Vikas

AU - Liesveld, Jane L.

AU - Litzow, Mark R.

AU - Miller, Alan M.

AU - Schouten, Harry C.

AU - Gale, Robert Peter

AU - Cahn, Jean Yves

AU - Weisdorf, Daniel J.

N1 - Funding Information: Financial Disclosure: The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases ; a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration; 2 grants ( N00014-06-1-0704 and N00014-08-1-0058 ) from the Office of Naval Research ; and grants from Allos, Inc. ; Amgen, Inc. ; Angioblast ; anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; HistoGenetics, Inc.; Kiadis Pharma; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; RemedyMD; Sanofi; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government.

PY - 2013/11

Y1 - 2013/11

N2 - Prediction of subsequent leukemia-free survival (LFS) and chronic graft-versus-host disease (GVHD) in adults with acute leukemia who survived at least 1 year after allogeneic hematopoietic cell transplantation is difficult. We analyzed 3339 patients with acute myeloid leukemia and 1434 patients with acute lymphoblastic leukemia who received myeloablative conditioning and related or unrelated stem cells from 1990 to 2005. Most clinical factors predictive of LFS in 1-year survivors were no longer significant after 2 or more years. For acute myeloid leukemia, only disease status (beyond first complete remission) remained a significant adverse risk factor for LFS 2 or more years after transplantation. For lymphoblastic leukemia, only extensive chronic GVHD remained a significant adverse predictor of LFS in the second and subsequent years. For patients surviving for 1 year without disease relapse or extensive chronic GVHD, the risk of developing extensive chronic GVHD in the next year was 4% if no risk factors were present and higher if noncyclosporine-based GVHD prophylaxis, an HLA-mismatched donor, or peripheral blood stem cells were used. Estimates for subsequent LFS and extensive chronic GVHD can be derived for individual patients or populations using an online calculator (http://www.cibmtr.org/LeukemiaCalculators). This prognostic information is more relevant for survivors than estimates provided before transplantation.

AB - Prediction of subsequent leukemia-free survival (LFS) and chronic graft-versus-host disease (GVHD) in adults with acute leukemia who survived at least 1 year after allogeneic hematopoietic cell transplantation is difficult. We analyzed 3339 patients with acute myeloid leukemia and 1434 patients with acute lymphoblastic leukemia who received myeloablative conditioning and related or unrelated stem cells from 1990 to 2005. Most clinical factors predictive of LFS in 1-year survivors were no longer significant after 2 or more years. For acute myeloid leukemia, only disease status (beyond first complete remission) remained a significant adverse risk factor for LFS 2 or more years after transplantation. For lymphoblastic leukemia, only extensive chronic GVHD remained a significant adverse predictor of LFS in the second and subsequent years. For patients surviving for 1 year without disease relapse or extensive chronic GVHD, the risk of developing extensive chronic GVHD in the next year was 4% if no risk factors were present and higher if noncyclosporine-based GVHD prophylaxis, an HLA-mismatched donor, or peripheral blood stem cells were used. Estimates for subsequent LFS and extensive chronic GVHD can be derived for individual patients or populations using an online calculator (http://www.cibmtr.org/LeukemiaCalculators). This prognostic information is more relevant for survivors than estimates provided before transplantation.

KW - Chronic graft-versus-host disease

KW - Landmark analysis

KW - Leukemia-free survival

KW - Prognosis

KW - Survivorship

UR - http://www.scopus.com/inward/record.url?scp=84885805664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885805664&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2013.08.013

DO - 10.1016/j.bbmt.2013.08.013

M3 - Article

C2 - 24018394

AN - SCOPUS:84885805664

SN - 1083-8791

VL - 19

SP - 1600

EP - 1607

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 11

ER -

Providing personalized prognostic information for adult leukemia survivors

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this